Related Experiment Video
Updated: Sep 11, 2025

Video Imaging and Spatiotemporal Maps to Analyze Gastrointestinal Motility in Mice
Published on: February 3, 2016
Disorders of gut-brain interaction in children: what is new
Darius Blanding1,2, Jaime Belkind-Gerson1,2, Alexandra Leigh Kilgore1,2
1Digestive Health Institute, Children's Hospital Colorado.
Insights
New insights reveal prenatal SSRI exposure and childhood experiences as key risk factors for pediatric disorders of gut-brain interactions (DGBIs). Management requires a multimodal approach combining medications, behavioral therapies, and neuromodulation for improved outcomes.
Area of Science:
- Pediatric Gastroenterology
- Neurogastroenterology
- Child Psychology
Background:
- Pediatric disorders of gut-brain interactions (DGBIs) affect up to 30% of children.
- Recent research has enhanced understanding of DGBIs' complex etiology and management.
Purpose of the Study:
- To review and synthesize recent (post-late 2023) literature on pediatric DGBIs.
- To cover predisposing factors, diagnostic tools, and therapeutic strategies.
Main Methods:
- Comprehensive literature review of studies published since late 2023.
- Synthesis of findings on risk factors, diagnostics, and treatments for pediatric DGBIs.
Main Results:
- Identified in utero SSRI exposure and adverse childhood experiences as significant risk factors.
- Highlighted the utility of gastric motility studies (e.g., dual-phase gastric emptying).
- Detailed advancements in pharmacologic (e.g., linaclotide) and nonpharmacologic (e.g., CBT, PNFS) therapies.
Conclusions:
- Pediatric DGBIs are multifactorial, with newly identified prenatal and psychosocial risk factors.
- A multimodal treatment strategy integrating pharmacologic, behavioral, and neuromodulation is supported.
- Further research and FDA approvals are needed to optimize pediatric DGBI management.
Purpose Of Review:
This review summarizes and expands upon studies published since late 2023 regarding predisposing factors, diagnostic measures, and both pharmacologic and nonpharmacologic therapies in the management of pediatric disorder of gut-brain interactions (DGBIs). With up to 30% of children affected by DGBIs, recent advances in diagnostics, therapeutics, and psychosocial insights continue to improve their clinical outcomes.
Recent Findings:
Recent literature underscores multifactorial contributors to DGBIs, including in utero SSRI exposure and adverse childhood experiences, as well as the potential benefit of gastric motility studies such as dual-phase gastric emptying and water load testing. Furthermore, this article describes advancements in the treatment of pediatric patients with DGBIs including pharmacologic treatments like linaclotide for pediatric functional constipation and nonpharmacologic therapies like percutaneous nerve field stimulation, cognitive behavioral therapy, and parent-focused interventions for many DGBI conditions.
Summary:
The most recent literature regarding pediatric DGBIs has newly identified in utero SSRI exposures in addition to psychosocial dynamics as risk factors for the conditions. Current literature supports the need for a multimodal approach to the treatment of pediatric DGBIs by integrating pharmacologic, behavioral, and neuromodulation. Further studies and expanded FDA approvals could further refine effective strategies for pediatric DGBIs.
More Related Videos
Related Concept Videos
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Other Disorders of Digestive System
Gastrointestinal Motility Disorders
Physiology of Enteric Nervous System and Gut Health
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:

